Pre-earnings options volume in Corvus Pharmaceuticals (CRVS) is normal with calls leading puts 8:5. Implied volatility suggests the market is anticipating a move near 12.0%, or $1.13, after results are released. Median move over the past eight quarters is 6.0%.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Is CRVS a Buy, Before Earnings?
- Corvus Pharmaceuticals upgraded to Outperform from Neutral at Mizuho
- Biotech Alert: Searches spiking for these stocks today
- Corvus Pharmaceuticals price target raised to $21 from $12 at Ladenburg
- Corvus Pharmaceuticals initiates registrational Phase 3 trial of soquelitinib